Qiagen NV  

(Public, FRA:QIA)   Watch this stock  
Find more results for QIA
+0.18 (0.71%)
Real-time:   10:28AM GMT+1
FRA real-time data - Disclaimer
Currency in EUR
Range 25.20 - 25.51
52 week 21.70 - 26.06
Open 25.20
Vol. 210.00
Mkt cap 5.94B
P/E 61.56
Div/yield     -
EPS 0.41
Shares 232.83M
Beta     -
Inst. own     -
Feb 2, 2016
Q4 2015 Qiagen NV Earnings Release - 10:00PM GMT+1 - Add to calendar
Jan 12, 2016
Qiagen NV at JPMorgan Healthcare Conference Add to calendar
Jan 12, 2016
Qiagen NV at Commerzbank German Investment Seminar Add to calendar
Dec 3, 2015
Qiagen NV at ISI Medtools Conference Add to calendar
Nov 19, 2015
Qiagen NV at Jefferies Global Healthcare Conference
Nov 12, 2015
Qiagen NV at Bryan Garnier European Healthcare Conference
Oct 29, 2015
Q3 2015 Qiagen NV Earnings Call
Oct 28, 2015
Q3 2015 Qiagen NV Earnings Release
Sep 25, 2015
Qiagen NV 2015 Private Investor Day
Sep 21, 2015
Qiagen NV at Berenberg and Goldman Sachs German Corporate Conference

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 10.81% 8.72%
Operating margin 14.68% 11.96%
EBITD margin - 32.41%
Return on average assets 3.29% 2.74%
Return on average equity 5.39% 4.35%
Employees 4,500 -
CDP Score - -


Spoorstraat 50
VENLO, 5911 KJ
+31-77-3208400 (Phone)
+31-77-3208409 (Fax)

Website links


QIAGEN N.V. (QIAGEN) is a Netherlands-based holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems. Sample to Insight molecular technologies are applicable across a range of applications and customer classes through more than 500 core consumable products, as well as instruments that automate the use of these products for sample preparation, analysis and interpretation. The Company's bioinformatics solutions connect laboratory workflows and process amounts of genomic data, enabling scientists or clinicians to interpret results and decide on further action.

Officers and directors

Peer M. Schatz Chief Executive Officer, Managing Director
Age: 49
Roland Sackers Chief Financial Officer, Managing Director
Age: 46
Thomas Schweins Senior Vice President - Human Resources, Strategy & Marketing Services
Dietrich Hauffe Senior Vice President - Life Sciences Business Area
Douglas Liu Senior Vice President - Global Operations
Helge Lubenow Senior Vice President - Molecular Diagnostics Business Area
Ulrich Schriek Senior Vice President - Corporate Business Development
Benedikt von Braunmuehl Senior Vice President - Global Commercial Operations
Stephane Bancel Independent Supervisory Director
Age: 42
Werner Brandt Independent Supervisory Director
Age: 61